<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

3 min read

Medtronic: Making Waves At NANS 2024

By Anne Staylor on 2/6/24 9:40 AM

Medtronic executives discuss how the Company is making waves in interventional pain, minimally invasive spine and deep brain stimulation in an interview with SmartTRAK at NANS 2024.

Medtronic’s David Carr, vice president and general manager of Pain Interventions, and Amaza Reitmeier, vice president and general manager of Brain Modulation, discuss the Company’s latest news, research and innovation in an interview with SmartTRAK at the North American Neuromodulation Society (NANS) 2024 Annual Meeting held January 18-21 in Las Vegas, Nevada.

To find out more, including the Company’s priorities and vision for interventional pain, minimally invasive spine and deep brain stimulation, click on the following video to listen to the interview (32:30 min). Topics by timecode are provided below, and you can click the button to download a transcript of the interview.

Download the Transcript

Interview Topics by Timecode:

00:27 David Carr introduction and background. Overview of Medtronic’s top news at NANS and the importance of the Company’s broad portfolio of pain intervention solutions, including stimulation, targeted drug delivery and interventional spine. 

04:28 Overview of Medtronic’s presence at NANS regarding clinical and scientific research vs competitors. Highlights of clinical data from Australian ECAPs study to support the introduction of the Inceptiv Spinal Cord Stimulation (SCS) system, what’s next for Inceptiv and how Inceptiv differs from other ECAP-based SCS devices. Discussion of other research and evidence to support expanded indications and health economics. Company strategies for leveraging data to drive adoption, reimbursement and growth in non-surgical refractory back pain and diabetic painful neuropathy (DPN),

Continue Reading
4 min read

SmartTRAK's Top 12 Blog Posts of 2023

By Thomas Wallick on 1/30/24 1:04 PM

Throughout 2023, SmartTRAK led the way in helping you Be The Expert in the MedTech industry. Serving as your trusted resource for the latest industry developments, we provided real-time market data and analysis across the orthopedic, wound care, regenerative medicine and neurotherapy sectors.  Presenting SmartTRAK's Top 12 Blog Posts from 2023, featuring indispensable insights from our expert analysts.

  1. Could Reverse Hips Change the Total Hip Game?
    Hip Innovation Technology is betting on its Reverse HRS Hip to change the practice of total hip replacement

  2. Three Ortho Robotics Companies to Watch in 2023
    SmartTRAK identifies three orthopedic robotics companies strategically positioned to shake things up this year in the fast-growing robotic-assisted TJA market.

  3. Saluda Medical: Changing the Game in Spinal Cord Stimulation
    Saluda Medical President and CEO Jim Schuermann discusses the Company, the Evoke System and changing the game in SCS in an interview with SmartTRAK.

    Request a Demo of the SmartTRAK Business Intelligence Platform

Continue Reading
7 min read

What’s New in Neuromodulation? News to Know Before NANS 2024

By Anne Staylor on 1/9/24 9:30 AM

The North American Neuromodulation Society (NANS) is celebrating its 30th anniversary in 2024 and is once again bringing together the leading clinicians, researchers and manufacturers to Caesar’s Palace in Las Vegas for the NANS 2024 Annual Meeting, to be held January 18-21. To get you up to speed before the meeting, SmartTRAK has put together highlights of recent neuromodulation news. The following is just a small sampling of recent Neuromodulation-related news and updates from around the world compiled, reviewed and posted in real-time every day by the expert analysts at SmartTRAK.

SmartTRAK will be attending NANS 2024 from January 18-21. If you'd like to meet with us in person, please reach out to Anne Staylor, SmartTRAK’s Executive Editor and VP & GM, Neuro Therapies, at anne.staylor@smarttrak.com, or just click the button below. Meet with SmartTRAK

Continue Reading
2 min read

BREAKING NEWS - Nevro Acquires VYRSA Technologies

By Anne Staylor on 12/1/23 1:49 PM

Nevro* (NVRO) announced it acquired VYRSA Technologies*, a privately held company focused on the minimally invasive treatment of chronic sacroiliac joint (SI Joint) pain. According to the Company, VYRSA is the only SI joint company that manufactures and supports a complete portfolio of FDA-cleared, state-of-the-art SI joint fusion devices. The acquisition was signed and closed on Nov 30, 2023. 

NVRO paid $40MM at closing and agreed to pay up to an additional $35MM in cash or stock tied to milestones. NVRO CEO Kevin Thornal said VYRSA offers differentiated implants to the Company’s current call point of physicians and will help drive company growth, adding that the technology will help bring long-term pain relief to the 15-30% of people suffering with chronic low back pain associated with the SI joint.

The US MIS SI Joint Fusion Market is the fastest-growing segment in the US Spine Market and a growing number of pain physicians are performing these procedures. According to SmartTRAK’s recently published 2023 US MIS SI Joint Market Report, this market is projected to grow at +18% CAGR over the next five years and 53+ MIS SI Joint Fusion systems are now commercially available in the US. See 2023 MIS SI Joint Fusion Market Report*.

The Company also announced the closing of a six-year, $200MM term loan credit facility to be used to repurchase the majority of its 2025 Convertible Notes and for working capital and other corporate purposes. NVRO CFO Rod MacLeod noted that the Company was pleased to refinance a majority of its debt and push the maturity out to 2029 while limiting equity dilution to 2.6MM warrant shares. 

Continue Reading
3 min read

SNIS 2023: New Frontiers in Stroke Care: An Interview with J Mocco, MD

By Anne Staylor on 9/19/23 9:45 AM

SNIS President J Mocco, MD, discusses emerging technologies and new frontiers in neurointervention in an interview with SmartTRAK.

J Mocco, MD, President of the Society of Neurointerventional Surgery (SNIS), discusses the latest research and innovation in stroke care in an interview with SmartTRAK at the 20thAnnual Meeting of the SNIS recently held in San Diego, CA. To find out more regarding important research, emerging technologies and new frontiers in stroke care, listen to the following video. (27:12 min). A complete transcript of the interview can be downloaded below.

SmartTRAK: Hi, this is Anne Staylor with SmartTRAK. Today I'm covering the Society of Neurointerventional Surgery annual meeting here in San Diego, and I have the pleasure of speaking to J Mocco, MD, president of the SNIS. Dr. Mocco, thank you for talking with me today.

J Mocco, MD: Thank you very much for having me.

Well, this year I felt a lot of energy and vibrancy at the meeting, particularly when I walked into the exhibit hall, which is nice after some of the years we've had with COVID. One of the things I wanted to ask you is what are some of the exciting research studies at SNIS this year? Maybe you could just highlight some of the key research that is presented here at the meeting.

Absolutely. I have to say this year was truly spectacular. The depth and breadth of new and exciting research and reports on technology and studies. This year we saw presentations on completely new technologies to treat brain aneurysms, multiple leap forwards in technologies to better remove clots from brains and cure people with stroke. Had very robust discussions on systems of care and how best to evaluate stroke patients. Is the current standard adequate? Should we have different methods of evaluating patient success? They're just examples of the really amazing things that are happening in this space in general, and particularly ...

To download the complete transcript of the interview with J Mocco, MD, President of SNIS, conducted by Anne Staylor, SmartTRAK Executive Editor, VP & GM of Neuro Therapies, just click the button below.Download the Transcript

Continue Reading
2 min read

Navigating Choppy Waters: Q422 Neuromodulation Market Recap

By Anne Staylor on 3/20/23 10:06 AM

While the macro environment is improving, some neuromodulation companies and segments navigated choppy waters in Q422

While the macro environment continued to improve in Q422, the waters remain choppy for some neuromodulation companies and segments.  Competitors are making gains on new and differentiated product offerings, strengthening demand and expanding indications. These gains are offset by the residual effects of the pandemic, reimbursement challenges, stubborn inflationary pressures and currency exchange headwinds." For FY22, the spinal cord stimulation (SCS) segment showed signs of recovery by year-end while deep brain stimulation (DBS) slowed on replacement headwinds for some companies.
Among the many topics covered in detail in our comprehensive Q422 Neuromodulation Market Recap* article:
  • Complete Q422 Neuromodulation Market Overview
  • SmartTRAK's Expert Market Analysis and Insights
  • All Company News, Revenues, Data, Charts and Shares
  • Spinal Cord Stimulation Sees Growth Exiting 2022
  • Macro Environment Improving
  • Innovation, Expanding Indications Driving Growth
  • Potential Payer Headwinds
  • DBS Slows on Replacement Headwinds, Share Shifts
  • Q422 Clinical/Regulatory Highlights
Continue Reading
2 min read

Saluda Medical: Changing the Game in Spinal Cord Stimulation

By Anne Staylor on 3/14/23 9:54 AM

Saluda Medical President and CEO Jim Schuermann discusses the Company, the Evoke System and changing the game in SCS in an interview with SmartTRAK

With the US launch of the Evoke System, Saluda Medical is changing the game in spinal cord stimulation (SCS). At the North American Neuromodulation Society (NANS) Annual meeting in Las Vegas in January, researchers presented impressive 36-month data from the Company’s Evoke Study and the Company was showcasing its Evoke System for the first time on the NANS exhibit hall floor. As the first commercially available closed-loop SCS system using evoked compound action potentials (ECAPs), Evoke is unlike anything on the market. The technology automatically adjusts stimulation to maintain precise and consistent neural activation to the spinal cord for the treatment of intractable low back and leg pain. The Company received FDA PMA for Evoke in February 2022 and announced a limited US commercial release in December 2022, calling it the first and only ‘SmartSCS” in the US.

Saluda Medical President and CEO Jim Schuermann discusses bringing Evoke System to market, the Company’s US launch and commercialization plans, the newest generation of Evoke, his vision for the future and Evoke’s potential impact on the market in an interview with SmartTRAK. Click the button below to download and read a complete transcript of the interview. Download the Interview Transcript

Continue Reading
3 min read

Spotlight on Medtronic Neuromodulation: NANS 2023

By Anne Staylor on 2/10/23 11:40 AM

Medtronic executives Nnamdi Njoku and Charlie Covert discuss Medtronic’s latest initiatives in Neuromodulation in an interview with SmartTRAK at NANS 2023

Nnamdi Njoku, Medtronic’s Senior Vice President and President Neuromodulation, and Charlie Covert, Vice President and General Manager of Pain Therapies, discuss what’s new for Medtronic Neuromodulation, expected market growth in 2023 and strategies for driving growth in spinal cord stimulation (SCS) and deep brain stimulation (DBS) in an interview with SmartTRAK at the North American Neuromodulation Society (NANS) 26th Annual Meeting held January 12-15, 2023 in Las Vegas, Nevada.

To find out more about the Company’s latest innovations, expanding indications and what’s next for Medtronic Neuromodulation, click on the following video recorded live at NANS 2023. (27:57 minutes.) Specific interview topics by time code are outlined below. A link to download a complete transcript of the interview is also provided below.

Continue Reading
2 min read

Emerging Technologies in Neurointervention

By Anne Staylor on 1/31/23 9:30 AM

SmartTRAK identifies emerging technologies at the most recent SNIS and ESMINT meetings that have the potential to disrupt the market for neurointervention.

In the market for neurovascular devices, companies continue to innovate and are focusing research and development efforts into novel technologies that could lead to improved outcomes and help fuel growth in the market for ischemic and hemorrhagic stroke devices. At two recent neurointerventional meetings, the Society for NeuroInterventional Surgery (SNIS) 19th Annual meeting and the 14th European Society for Minimally Invasive Neurological Therapy (ESMINT) Congress 2022, SmartTRAK identified emerging technologies that could potentially disrupt the neurovascular market over the next two to five years. This includes enabling technologies for neurointerventional procedures, novel approaches to aspiration for the treatment of acute ischemic stroke (AIS) and innovation in intrasaccular flow disruption devices.

Among the many interesting topics covered in this informative article are:

  • Enabling Technologies for Neurointervention
    • Corindus' CorPath GRX System
    • Robotic-assisted Neuroendovascular Navigation
  • Update on Aspiration
    • Cyclical Aspiration
    • Modulated Aspiration
  • Advances in Intrasaccular Flow Disruption Devices
Continue Reading
2 min read

Neuromodulation Trends: SmartTRAK at NANS 2023

By Thomas Wallick on 1/10/23 9:00 AM

SmartTRAK takes a look back at Neuromodulation Trends in 2022 and looks forward to reporting on emerging trends at NANS 2023

Anne Staylor, SmartTRAK's Executive Editor VP & GM, Neuro Therapies, will again be attending and reporting on the North American Neuromodulation Society Annual Meeting (NANS), this year being held in Las Vegas, January 12-15th. If you would like to meet with Anne while at NANS, just click here.

Last year, Anne published a prescient article from the NANS 25th Annual Meeting titled "Neuromodulation Trends in 2022 and Beyond" in which she identified key trends from the meeting in Orlando and provided an outlook of what’s on the horizon for neuromodulation. This included trends in research and technology that will help shape the markets for spinal cord stimulation (SCS), deep brain stimulation (DBS) and peripheral nerve stimulation (PNS), advances in closed-loop therapies, improving care through digital solutions and driving growth through expanding indications.

To download and read the complete "Neuromodulation Trends in 2022 and Beyond" article, just click here.  

Continue Reading
  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles